You are here

Article Text

Article menu
Download PDFPDF
Treatment
Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations

https://doi.org/10.1136/ebn.8.3.78

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129–36.OpenUrlCrossRefPubMedWeb of Science

    Q In patients with asthma, is budesonide (BUD) plus formoterol (FORM) (BUDFORM) for both maintenance and symptom relief more effective than fixed dosing using BUDFORM or a 4 fold higher dose of BUD, both with a short acting β2 agonist (SABA), for reducing the rate of severe asthma exacerbations?

    METHODS

    Embedded ImageDesign:

    randomised controlled trial.

    Embedded ImageAllocation:

    concealed.

    Embedded ImageBlinding:

    blinded (patients and healthcare providers).

    Embedded ImageFollow up period:

    1 year

    Embedded ImageSetting:

    246 centres in 22 countries.

    Embedded ImagePatients:

    2760 outpatients (mean age 36 y, 55% women/girls; 12% children 4–11 y) with asthma who were using inhaled corticosteroids (ICSs).

    Embedded ImageIntervention:

    BUDFORM (BUD, 80 μg plus FORM, 4.5 μg) both for …

    View Full Text

    Footnotes

    • For correspondence: Dr P M O’Byrne, St Joseph’s Hospital, Hamilton, Ontario, Canada. obyrnepmcmaster.ca

    • Source of funding: AstraZeneca R&D, Lund, Sweden.